A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Sponsor: |
Regeneron Pharmaceuticals, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS4125 |
U.S. Govt. ID: |
NCT03969004 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is determine if cemiplimab will prevent Cutaneous Squamous Cell Cancer (CSCC) from returning after surgery and radiation.
This study is closed
Investigator
Shaheer Khan, DO
Are you 18 years of age or older? |
Yes |
No |
Were you diagnosed with Cutaneous Squamous Cell Cancer (CSCC)? |
Yes |
No |
Are you able to understand and complete study-related questionnaires? |
Yes |
No |